Overview An estimated 36,800 people will die of pancreatic cancer in the United States in 2010.1 This disease is the fourth most common cause of cancer-related death among men and women in the United States.1 Its peak incidence occurs in the seventh and eighth decades of life. Although incidence is roughly equal for the sexes, African Americans seem to have a higher incidence of pancreatic cancer than white Americans.2 These guidelines only discuss tumors of the exocrine pancreas; neuroendocrine tumors are not included. By definition, these NCCN Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Exceptions to the rule were discussed among the panel members during development of these guidelines. A 5% rule (omitting clinical scenarios that constitute fewer than 5% of all cases) was used to eliminate uncommon clinical occurrences or conditions from these guidelines. The panel unanimously endorses participation in a clinical trial as the preferred option over standard or accepted therapy. Risk Factors and Genetic Predisposition Although the associated increase in risk is small, the development of pancreatic cancer is firmly linked to cigarette smoking.3–5 Some evidence shows that increased consumption of red meat and dairy products is associated with an elevation in pancreatic cancer risk,6 although other studies have failed to identify dietary risk factors.4 An increased body mass index is also associated with increased risk.7–9 Occupational exposure to chemicals, such as beta-naphthylamine and benzidine, is also associated with an increased risk of pancreatic...
  • 1.

    American Cancer Society. Facts & Figures 2010. Atlanta: American Chemical Society; 2010.

  • 2.

    ArnoldLDPatelAVYanY. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity. Cancer Epidemiol Biomarkers Prev2009;18:23972405.

    • Search Google Scholar
    • Export Citation
  • 3.

    LynchSMVrielingALubinJH. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol2009;170:403413.

    • Search Google Scholar
    • Export Citation
  • 4.

    RaimondiSMaisonneuveRLowenfelsAB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol2009;6:699708.

  • 5.

    VrielingABueno-de-MesquitaHB. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk on the European prospective investigation into cancer and nutrition. Int J Cancer2010;126:23942403.

    • Search Google Scholar
    • Export Citation
  • 6.

    ThiebautACJiaoLSilvermanDT. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst2009;101:10011011.

    • Search Google Scholar
    • Export Citation
  • 7.

    LarssonSCOrsiniNWolkA. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer2007;120:19931998.

    • Search Google Scholar
    • Export Citation
  • 8.

    LiDMorrisJSLiuJ. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA2009;301:25532562.

  • 9.

    PatelAVRodriguezCBernsteinL. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev2005;14:459466.

    • Search Google Scholar
    • Export Citation
  • 10.

    MancusoTFel-AttarAA. Cohort study of workers exposed to beta naphthylamine and benzidine. J Occup Med1967;9:277285.

  • 11.

    GuptaSVittinghoffEBertenthalD. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol2006;4:13661372.

  • 12.

    MekanSFSafaMMKomrokjiRS. Is hyperglycemia a prognostic factor in pancreatic cancer? [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 14076.

    • Search Google Scholar
    • Export Citation
  • 13.

    ChariSTLeibsonCLRabeKG. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology2005;129:504511.

    • Search Google Scholar
    • Export Citation
  • 14.

    PezzilliRCasadeiRMorselli-LabateAM. Is type 2 diabetes a risk factor for pancreatic cancer?JOP2009;10:705706.

  • 15.

    LiDYeungSCHassanMM. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology2009;137:482488.

  • 16.

    LowenfelsABMaisonneuvePCavalliniG. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med1993;328:14331437.

    • Search Google Scholar
    • Export Citation
  • 17.

    MalkaDHammelPMaireF. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut2002;51:849852.

  • 18.

    LynchHTSmyrkTKernSE. Familial pancreatic cancer: a review. Semin Oncol1996;23:251275.

  • 19.

    WangWChenSBruneKA. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol2007;25:14171422.

    • Search Google Scholar
    • Export Citation
  • 20.

    WhelanAJBartschDGoodfellowPJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med1995;333:975977.

    • Search Google Scholar
    • Export Citation
  • 21.

    GhiorzoPGargiuloSNastiS. Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanomapancreatic cancer syndrome in Italy. J Clin Oncol2007;25:53365337.

    • Search Google Scholar
    • Export Citation
  • 22.

    HahnSAGreenhalfBEllisI. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst2003;95:214221.

  • 23.

    FerroneCRLevineDATangLH. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol2009;27:433438.

  • 24.

    SlaterEPLangerPNiemczykE. PALB2 mutations in European familial pancreatic cancer families. Clin Genet2010; in press.

  • 25.

    CantoMIGogginsMYeoCJ. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol2004;2:606621.

    • Search Google Scholar
    • Export Citation
  • 26.

    PoleyJWKlujitIGoumaDJ. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol2009;104:21752181.

    • Search Google Scholar
    • Export Citation
  • 27.

    LangerPKannPHFendrichV. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut2009;58:14101418.

    • Search Google Scholar
    • Export Citation
  • 28.

    RosaJAVan LindaBMAbourizkNN. New-onset diabetes mellitus as a harbinger of pancreatic carcinoma. A case report and literature review. J Clin Gastroenterol1989;11:211215.

    • Search Google Scholar
    • Export Citation
  • 29.

    GirelliCMReguzzoniGLimidoE. Pancreatic carcinoma: differences between patients with or without diabetes mellitus. Recent Prog Med1995;86:143146.

    • Search Google Scholar
    • Export Citation
  • 30.

    AgarwalBAbu-HamdaEMolkeKL. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol2004;99:844850.

    • Search Google Scholar
    • Export Citation
  • 31.

    JohnsonCD. Pancreatic carcinoma: developing a protocol for multi-detector row CT. Radiology2001;220:34.

  • 32.

    WongJCLuDS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol2008;6:13011308.

  • 33.

    CalleryMPChangKJFishmanEK. Pretreatment assessment of resectable and borderline resectable pancreatic cancer. Ann Surg Oncol2009;16:17271733.

    • Search Google Scholar
    • Export Citation
  • 34.

    HouseMGYeoCJCameronJL. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg2004;8:280288.

    • Search Google Scholar
    • Export Citation
  • 35.

    KlaubMSchobingerMWolfI. Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol2009;15:58275832.

    • Search Google Scholar
    • Export Citation
  • 36.

    FuhrmanGMCharnsangavejCAbbruzzeseJL. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg1994;167:104111.

    • Search Google Scholar
    • Export Citation
  • 37.

    WolffRAEvansDBCraneCH. Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma [abstract]. J Clin Oncol2002;21(Suppl 1):Abstract 516.

    • Search Google Scholar
    • Export Citation
  • 38.

    TalamontiMSSmallWJrMulcahyMF. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol2006;13:150158.

    • Search Google Scholar
    • Export Citation
  • 39.

    HortonKMFishmanEK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am2002;40:12631272.

  • 40.

    McNultyNJFrancisIRPlattJF. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology2001;220:97102.

    • Search Google Scholar
    • Export Citation
  • 41.

    SchimaWFuggerRSchoberE. Diagnosis and staging of pancreatic cancer: comparison of mangfodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. AJR Am J Roentgenol2002;179:717724.

    • Search Google Scholar
    • Export Citation
  • 42.

    FarmaJMSantillanAAMelisM. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol2008;15:24652471.

    • Search Google Scholar
    • Export Citation
  • 43.

    PanwalkarAGremJHaukeR. Imaging in pancreatic cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21 2007; Orlando Florida. Abstract 125.

    • Search Google Scholar
    • Export Citation
  • 44.

    RoschTBraigCGainT. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology1992;102:188199.

    • Search Google Scholar
    • Export Citation
  • 45.

    VaradarajuluSWallaceMB. Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control2004;11:1522.

  • 46.

    SantoE. Pancreatic cancer imaging: which method?JOP2004;5:253257.

  • 47.

    InoueKOhuchidaJOhtsukaT. Severe localized stenosis and marked dilatation of the main pancreatic duct are indicators of pancreatic cancer instead of chronic pancreatitis on endoscopic retrograde balloon pancreatography. Gastrointest Endosc2003;58:510515.

    • Search Google Scholar
    • Export Citation
  • 48.

    WarshawALGuZYWittenbergJWaltmanAC. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg1990;125:230233.

    • Search Google Scholar
    • Export Citation
  • 49.

    AhmedSIBochkarevVOleynikovDSassonAR. Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A2006;16:458463.

    • Search Google Scholar
    • Export Citation
  • 50.

    PistersPWHudecWAHessKR. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg2001;234:4755.

    • Search Google Scholar
    • Export Citation
  • 51.

    AnderssonRVagianosCEWilliamsonRC. Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford)2004;6:512.

    • Search Google Scholar
    • Export Citation
  • 52.

    KarachristosAScarmesasNHoffmanJP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg2005;9:12861292.

    • Search Google Scholar
    • Export Citation
  • 53.

    WhiteRWinstonCGonenM. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg2008;206:445450.

    • Search Google Scholar
    • Export Citation
  • 54.

    FerroneCRHaasBTangL. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg2006;10:13471353.

    • Search Google Scholar
    • Export Citation
  • 55.

    SafiFRoscherRBittnerR. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas1987;2:398403.

    • Search Google Scholar
    • Export Citation
  • 56.

    MannDVEdwardsRHoS. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol2000;26:474479.

    • Search Google Scholar
    • Export Citation
  • 57.

    TemperoMAUchidaETakasakiH. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res1987;47:55015503.

    • Search Google Scholar
    • Export Citation
  • 58.

    FerroneCRFinkelsteinDMThayerSP. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol2006;24:28972902.

    • Search Google Scholar
    • Export Citation
  • 59.

    BergerACGarciaMJrHoffmanJP. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol2008;26:59185922.

    • Search Google Scholar
    • Export Citation
  • 60.

    KondoNMurakamiYUemuraK. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncolin press.

    • Search Google Scholar
    • Export Citation
  • 61.

    HessVGlimeliusBGraweP. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol2008;9:132138.

    • Search Google Scholar
    • Export Citation
  • 62.

    IshiiHOkadaSSatoT. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology1997;44:279283.

    • Search Google Scholar
    • Export Citation
  • 63.

    HalmUSchumannTSchiefkeI. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer2000;82:10131016.

    • Search Google Scholar
    • Export Citation
  • 64.

    KoAHHwangJVenookAP. Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer2005;93:195199.

    • Search Google Scholar
    • Export Citation
  • 65.

    WongDKoAHHwangJ. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas2008;37:269274.

    • Search Google Scholar
    • Export Citation
  • 66.

    KaladyMFPetersonBBaillieJ. Pancreatic duct strictures: identifying risk of malignancy. Ann Surg Oncol2004;11:581588.

  • 67.

    MengesMLerchMMZeitzM. The double duct sign in patients with malignant and benign pancreatic lesions. Gastrointest Endosc2000;52:7477.

    • Search Google Scholar
    • Export Citation
  • 68.

    NIH state-of-the-science statement on endoscopic retrograde cholangiopancreatography (ERCP) for diagnosis and therapy. NIH Consens State Sci Statements2002;19:126.

    • Search Google Scholar
    • Export Citation
  • 69.

    CampisiABrancatelliGVulliermeMP. Are pancreatic calcifications specific for the diagnosis of chronic pancreatitis? A multidetector-row CT analysis. Clin Radiol2009;64:903911.

    • Search Google Scholar
    • Export Citation
  • 70.

    KajiwaraMKojimaMKonishiM. Autoimmune pancreatitis with multifocal lesions. J Hepatobiliary Pancreat Surg2008;15:449452.

  • 71.

    LawRBronnerMVogtDStevensT. Autoimmune pancreatitis: a mimic of pancreatic cancer. Cleve Clin J Med2009;76:607615.

  • 72.

    SallaGChatzipantelisPLonstantinouP. EUS-FNA contribution in the identification of autoimmune pancreatitis: a case report. JOP2007;8:598604.

    • Search Google Scholar
    • Export Citation
  • 73.

    FinkelbergDLSahaniDDeshpandeVBruggeWR. Autoimmune pancreatitis. N Engl J Med2006;355:26702676.

  • 74.

    MicamesCJowellPSWhiteR. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc2003;58:690695.

    • Search Google Scholar
    • Export Citation
  • 75.

    BhutaniMS. Role of endoscopic ultrasonography in the diagnosis and treatment of cystic tumors of the pancreas. JOP2004;5:266272.

  • 76.

    EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual 7th edition. New York: Springer; 2010.

  • 77.

    BilimoriaKYBentremDJKoCY. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer2007;110:738744.

    • Search Google Scholar
    • Export Citation
  • 78.

    VerbekeCS. Resection margins and R1 rates in pancreatic cancer—are we there yet?Histopathology2008;52:787796.

  • 79.

    StaleyCAClearyKRAbbruzzeseJL. The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas1996;12:373380.

    • Search Google Scholar
    • Export Citation
  • 80.

    LuttgesJZamboniGKloppelG. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas. A proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist. Dig Surg1999;16:291296.

    • Search Google Scholar
    • Export Citation
  • 81.

    RautCPTsengJFSunCS. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg2007;246:5260.

    • Search Google Scholar
    • Export Citation
  • 82.

    LiDXieKWolffRAbbruzzeseJL. Pancreatic cancer. Lancet2004;363:10491057.

  • 83.

    GudjonssonB. Cancer of the pancreas. 50 years of surgery. Cancer1987;60:22842303.

  • 84.

    CristDWSitzmannJVCameronJL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg1987;206:358365.

    • Search Google Scholar
    • Export Citation
  • 85.

    YeoCJAbramsRAGrochowLB. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg1997;225:621633.

    • Search Google Scholar
    • Export Citation
  • 86.

    AllisonDCPiantadosiSHrubanRH. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol1998;67:151159.

    • Search Google Scholar
    • Export Citation
  • 87.

    SohnTAYeoCJCameronJL. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg2000;4:567579.

    • Search Google Scholar
    • Export Citation
  • 88.

    HowardTJKrugJEYuJ. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg2006;10:13381345.

    • Search Google Scholar
    • Export Citation
  • 89.

    ZervosEERosemurgyASAl-SaifODurkinAJ. Surgical management of early-stage pancreatic cancer. Cancer Control2004;11:2331.

  • 90.

    VaradhacharyGRTammEPAbbruzzeseJL. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol2006;13:10351046.

    • Search Google Scholar
    • Export Citation
  • 91.

    TalamontiM. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol2006;13:10191020.

  • 92.

    BottgerTCJungingerT. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg1999;23:164171.

    • Search Google Scholar
    • Export Citation
  • 93.

    LerutJPGianelloPROtteJBKestensPJ. Pancreaticoduodenal resection. Surgical experience and evaluation of risk factors in 103 patients. Ann Surg1984;199:432437.

    • Search Google Scholar
    • Export Citation
  • 94.

    BraaschJWGrayBN. Considerations that lower pancreatoduodenectomy mortality. Am J Surg1977;133:480484.

  • 95.

    HeslinMJBrooksADHochwaldSN. A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy. Arch Surg1998;133:149154.

    • Search Google Scholar
    • Export Citation
  • 96.

    LaiECMokFPFanST. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg1994;81:11951198.

  • 97.

    McPhersonGABenjaminISHodgsonHJ. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Br J Surg1984;71:371375.

    • Search Google Scholar
    • Export Citation
  • 98.

    PittHAGomesASLoisJF. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?Ann Surg1985;201:545553.

    • Search Google Scholar
    • Export Citation
  • 99.

    ThomasJHConnorCSPierceGE. Effect of biliary decompression on morbidity and mortality of pancreatoduodenectomy. Am J Surg1984;148:727731.

    • Search Google Scholar
    • Export Citation
  • 100.

    HatfieldARTobiasRTerblancheJ. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet1982;2:896899.

    • Search Google Scholar
    • Export Citation
  • 101.

    GundrySRStrodelWEKnolJA. Efficacy of preoperative biliary tract decompression in patients with obstructive jaundice. Arch Surg1984;119:703708.

    • Search Google Scholar
    • Export Citation
  • 102.

    PovoskiSPKarpehMSJrConlonKC. Preoperative biliary drainage: impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy. J Gastrointest Surg1999;3:496505.

    • Search Google Scholar
    • Export Citation
  • 103.

    PistersPWHudecWAHessKR. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg2001;234:4755.

    • Search Google Scholar
    • Export Citation
  • 104.

    van der GaagNARauwsEAJvan EijckCHJ. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med2010;362:129137.

    • Search Google Scholar
    • Export Citation
  • 105.

    TraversoLWLongmireWPJr. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet1978;146:959962.

  • 106.

    YeoCJCameronJLSohnTA. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg1997;226:248257.

    • Search Google Scholar
    • Export Citation
  • 107.

    van Berge HenegouwenMIMoojenTMvan GulikTM. Postoperative weight gain after standard Whipple's procedure versus pylorus-preserving pancreatoduodenectomy: the influence of tumour status. Br J Surg1998;85:922926.

    • Search Google Scholar
    • Export Citation
  • 108.

    KozuschekWReithHBWaleczekH. A comparison of long term results of the standard Whipple procedure and the pylorus preserving pancreatoduodenectomy. J Am Coll Surg1994;178:443453.

    • Search Google Scholar
    • Export Citation
  • 109.

    SeilerCAWagnerMSadowskiC. Randomized prospective trial of pylorus-preserving vs. classic duodenopancreatectomy (Whipple procedure): initial clinical results. J Gastrointest Surg2000;4:443452.

    • Search Google Scholar
    • Export Citation
  • 110.

    MorelPMatheyPCorboudH. Pylorus-preserving duodenopancreatectomy: long-term complications and comparison with the Whipple procedure. World J Surg1990;14:642646.

    • Search Google Scholar
    • Export Citation
  • 111.

    LinPWLinYJ. Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. Br J Surg1999;86:603607.

    • Search Google Scholar
    • Export Citation
  • 112.

    RoderJDSteinHJHuttlWSiewertJR. Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg1992;79:152155.

    • Search Google Scholar
    • Export Citation
  • 113.

    YeoCJCameronJLMaherMM. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg1995;222:580588.

    • Search Google Scholar
    • Export Citation
  • 114.

    SikoraSSPosnerMC. Management of the pancreatic stump following pancreaticoduodenectomy. Br J Surg1995;82:15901597.

  • 115.

    BassiCFalconiMMolinariE. Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. Surgery2003;134:766771.

    • Search Google Scholar
    • Export Citation
  • 116.

    StrasbergSMDrebinJAMokadamNA. Prospective trial of a blood supply-based technique of pancreaticojejunostomy: effect on anastomotic failure in the Whipple procedure. J Am Coll Surg2002;194:746760.

    • Search Google Scholar
    • Export Citation
  • 117.

    WinterJMCameronJLCampbellKA. Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg2006;10:12801290.

    • Search Google Scholar
    • Export Citation
  • 118.

    BalcomJHRattnerDWWarshawAL. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg2001;136:391398.

    • Search Google Scholar
    • Export Citation
  • 119.

    BassiCDervenisCButturiniG. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery2005;138:813.

  • 120.

    YeoCJCameronJLLillemoeKD. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg2000;232:419429.

    • Search Google Scholar
    • Export Citation
  • 121.

    LowyAMLeeJEPistersPW. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg1997;226:632641.

    • Search Google Scholar
    • Export Citation
  • 122.

    LillemoeKDCameronJLKimMP. Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg2004;8:766772.

    • Search Google Scholar
    • Export Citation
  • 123.

    FortnerJG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg1984;199:418425.

    • Search Google Scholar
    • Export Citation
  • 124.

    FuhrmanGMLeachSDStaleyCA. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg1996;223:154162.

    • Search Google Scholar
    • Export Citation
  • 125.

    LeachSDLeeJECharnsangavejC. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg1998;85:611617.

    • Search Google Scholar
    • Export Citation
  • 126.

    LaunoisBStasikCBardaxoglouE. Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer?World J Surg1999;23:926929.

    • Search Google Scholar
    • Export Citation
  • 127.

    TaschieriAMElliMRovatiM. Surgical treatment of pancreatic tumors invading the spleno-mesenteric-portal vessels. An Italian Multicenter Survey. Hepatogastroenterology1999;46:492497.

    • Search Google Scholar
    • Export Citation
  • 128.

    ClavienPARudigerHA. A simple technique of portal vein resection and reconstruction during pancreaticoduodenectomy. J Am Coll Surg1999;189:629634.

    • Search Google Scholar
    • Export Citation
  • 129.

    van GeenenRCten KateFJde WitLT. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery2001;129:158163.

    • Search Google Scholar
    • Export Citation
  • 130.

    TsengJFRautCPLeeJE. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg2004;8:935949.

    • Search Google Scholar
    • Export Citation
  • 131.

    CubillaALFortnerJFitzgeraldPJ. Lymph node involvement in carcinoma of the head of the pancreas area. Cancer978;41:880887.

  • 132.

    NagaiHKurodaAMoriokaY. Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg1986;204:6571.

    • Search Google Scholar
    • Export Citation
  • 133.

    PistersPBrennanM. Regional lymph node dissection for pancreatic adenocarcinoma. In: EvansDPistersPAbbruzzeseJ eds. Pancreatic Cancer. New York: Springer-Verlag; 2002:139151.

    • Search Google Scholar
    • Export Citation
  • 134.

    IshikawaOOhhigashiHSasakiY. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg1988;208:215220.

    • Search Google Scholar
    • Export Citation
  • 135.

    ManabeTOhshioGBabaN. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer1989;64:11321137.

  • 136.

    GeerRJBrennanMF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg1993;165:6872.

  • 137.

    Henne-BrunsDVogelILuttgesJ. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg2000;24:595601.

    • Search Google Scholar
    • Export Citation
  • 138.

    PedrazzoliSDiCarloVDionigiR. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg1998;228:508517.

    • Search Google Scholar
    • Export Citation
  • 139.

    YeoCJCameronJLSohnTA. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg1999;229:613622.

    • Search Google Scholar
    • Export Citation
  • 140.

    YeoCJCameronJLLillemoeKD. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg2002;236:355366.

    • Search Google Scholar
    • Export Citation
  • 141.

    EdgeSBSchmiegREJrRosenlofLKWilhelmMC. Pancreas cancer resection outcome in American University centers in 1989–1990. Cancer1993;71:35023508.

    • Search Google Scholar
    • Export Citation
  • 142.

    LiebermanMDKilburnHLindseyMBrennanMF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg1995;222:638645.

    • Search Google Scholar
    • Export Citation
  • 143.

    GordonTABurleysonGPTielschJMCameronJL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg1995;221:4349.

    • Search Google Scholar
    • Export Citation
  • 144.

    ImperatoPJNennerRPStarrHA. The effects of regionalization on clinical outcomes for a high risk surgical procedure: a study of the Whipple procedure in New York state. Am J Med Qual1996;11:193197.

    • Search Google Scholar
    • Export Citation
  • 145.

    RosemurgyASBloomstonMSerafiniFM. Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg2001;5:2126.

    • Search Google Scholar
    • Export Citation
  • 146.

    SosaJABowmanHMGordonTA. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg1998;228:429438.

  • 147.

    HoVHeslinMJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg2003;237:509514.

  • 148.

    SimunovicMToTTheriaultMLangerB. Relation between hospital surgical volume and outcome for pancreatic resection for neoplasm in a publicly funded health care system. CMAJ1999;160:643648.

    • Search Google Scholar
    • Export Citation
  • 149.

    GoumaDJvan GeenenRCvan GulikTM. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg2000;232:786795.

    • Search Google Scholar
    • Export Citation
  • 150.

    BirkmeyerJDFinlaysonSRTostesonAN. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery1999;125:250256.

    • Search Google Scholar
    • Export Citation
  • 151.

    BirkmeyerJDSiewersAEFinlaysonEV. Hospital volume and surgical mortality in the United States. N Engl J Med2002;346:11281137.

  • 152.

    BilimoriaKYBentremDJKoCY. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer2007;110:12271234.

    • Search Google Scholar
    • Export Citation
  • 153.

    BilimoriaKYBentremDJKoCY. National failure to operate on early stage pancreatic cancer. Ann Surg2007;246:173180.

  • 154.

    KalserMHEllenbergSS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg1985;120:899903.

    • Search Google Scholar
    • Export Citation
  • 155.

    KlinkenbijlJHJeekelJSahmoudT. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg1999;230:776782.

    • Search Google Scholar
    • Export Citation
  • 156.

    SmeenkHGvan EijckCHHopWC. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation. Ann Surg2007;246:734740.

    • Search Google Scholar
    • Export Citation
  • 157.

    NeoptolemosJPStockenDDFriessH. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med2004;350:12001210.

    • Search Google Scholar
    • Export Citation
  • 158.

    KoshyMCLandryJCCavanaughSX. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys2005;61:965966.

  • 159.

    CraneCHBen-JosefESmallWJr. Chemotherapy for pancreatic cancer. N Engl J Med2004;350:27132715; author reply 2713–2715.

  • 160.

    OettleHPostSNeuhausP. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA2007;297:267277.

    • Search Google Scholar
    • Export Citation
  • 161.

    NeuhausPRiessHPostS. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract LBA 4504.

    • Search Google Scholar
    • Export Citation
  • 162.

    RegineWFWinterKWAbramsRA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. JAMA2008;299:10191026.

    • Search Google Scholar
    • Export Citation
  • 163.

    GarofaloMCAbramsRARegineWF. Adjuvant therapy for pancreatic cancer: no `definite' standard. Oncology2007;21:726730.

  • 164.

    NeoptolemosJBuchlerMStockenDD. ESPAC-3 (2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract LBA4505.

    • Search Google Scholar
    • Export Citation
  • 165.

    WolffRAVaradhacharyGREvansDB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol2008;15:27732786.

    • Search Google Scholar
    • Export Citation
  • 166.

    MehtaVKPoenJCFordJM. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol2001;24:155159.

    • Search Google Scholar
    • Export Citation
  • 167.

    HuguetFAndreTHammelP. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol2007;25:326331.

    • Search Google Scholar
    • Export Citation
  • 168.

    KrishnanSRanaVJanjanNA. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer2007;110:4755.

    • Search Google Scholar
    • Export Citation
  • 169.

    HuguetFGirardNSeblain-El GuercheC. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma. J Clin Oncol2009;27:22692277.

    • Search Google Scholar
    • Export Citation
  • 170.

    MornexFGirardNDelperoJRPartenskyC. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment. Semin Radiat Oncol2005;15:226234.

    • Search Google Scholar
    • Export Citation
  • 171.

    QuirosRMBrownKMHoffmanJP. Neoadjuvant therapy in pancreatic cancer. Cancer Invest2007;25:267273.

  • 172.

    HoffmanJPLipsitzSPisanskyT. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol1998;16:317323.

    • Search Google Scholar
    • Export Citation
  • 173.

    BreslinTMHessKRHarbisonDB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol2001;8:123132.

    • Search Google Scholar
    • Export Citation
  • 174.

    SpitzFRAbbruzzeseJLLeeJE. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol1997;15:928937.

    • Search Google Scholar
    • Export Citation
  • 175.

    WhiteRRHurwitzHIMorseMA. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol2001;8:758765.

  • 176.

    EvansDBRichTAByrdDR. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg1992;127:13351339.

    • Search Google Scholar
    • Export Citation
  • 177.

    HoffmanJPWeeseJLSolinLJ. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg1995;169:7177; discussion 77–78.

    • Search Google Scholar
    • Export Citation
  • 178.

    PalmerDHStockenDDBuckelsJA. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone vs. gemcitabine combined with cisplatin. J Clin Oncol2007;14:20882096.

    • Search Google Scholar
    • Export Citation
  • 179.

    MassuccoPCapussottiLMagninoA. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol2006;13:12011208.

    • Search Google Scholar
    • Export Citation
  • 180.

    AmmoriJBCollettiLMZalupskiMM. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg2003;7:766772.

    • Search Google Scholar
    • Export Citation
  • 181.

    PingpankJFHoffmanJPRossEA. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg2001;5:121130.

    • Search Google Scholar
    • Export Citation
  • 182.

    PalmerDHStockenDDHewittH. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol2007;14:20882096.

    • Search Google Scholar
    • Export Citation
  • 183.

    EvansDBVaradhacharyGRCraneCH. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol2008;26:34963502.

    • Search Google Scholar
    • Export Citation
  • 184.

    VaradhacharyGRWolffRACraneCH. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol2008;26:34873495.

    • Search Google Scholar
    • Export Citation
  • 185.

    KimRSaifMW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?JOP2007;8:279288.

  • 186.

    MoertelCGFrytakSHahnRG. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer1981;48:17051710.

    • Search Google Scholar
    • Export Citation
  • 187.

    BozGDe PaoliAInnocenteR. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys2001;51:736740.

    • Search Google Scholar
    • Export Citation
  • 188.

    ShibuyaKOyaNFujiiT. Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol2010; in press.

    • Search Google Scholar
    • Export Citation
  • 189.

    GirardNMornexFBossardN. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 phase I trial. Int J Radiat Oncol Biol Phys2010;77:14261432.

    • Search Google Scholar
    • Export Citation
  • 190.

    MurphyJDAdusumilliSGriffithKA. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys2007;68:801808.

    • Search Google Scholar
    • Export Citation
  • 191.

    CraneCHAbbruzzeseJLEvansDB. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?Int J Radiat Oncol Biol Phys2002;52:12931302.

    • Search Google Scholar
    • Export Citation
  • 192.

    HaddockMGSwaminathanRFosterNR. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group phase II study N9942. J Clin Oncol2007;25:25672572.

    • Search Google Scholar
    • Export Citation
  • 193.

    KoAHQuiveyJMVenookAP. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys2007;68:809816.

    • Search Google Scholar
    • Export Citation
  • 194.

    KlassenDJMacIntyreJMCattonGE. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol1985;3:373378.

    • Search Google Scholar
    • Export Citation
  • 195.

    Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst1988;80:751755.

    • Search Google Scholar
    • Export Citation
  • 196.

    LoehrerPJPowellMECardenesHR. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4506.

    • Search Google Scholar
    • Export Citation
  • 197.

    ChauffertBMornexFBonnetainF. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol2008;18:15921599.

    • Search Google Scholar
    • Export Citation
  • 198.

    BurrisHAIIIMooreMJAndersenJ. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol1997;15:24032413.

    • Search Google Scholar
    • Export Citation
  • 199.

    GrunewaldRAbbruzzeseJLTarassoffPPlunkettW. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol1991;27:258262.

    • Search Google Scholar
    • Export Citation
  • 200.

    TemperoMPlunkettWRuiz Van HaperenV. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol2003;21:34023408.

    • Search Google Scholar
    • Export Citation
  • 201.

    PoplinEFengYBerlinJ. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol2009;27:37783785.

    • Search Google Scholar
    • Export Citation
  • 202.

    DemolsAPeetersMPolusM. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer2006;94:481485.

    • Search Google Scholar
    • Export Citation
  • 203.

    FineRLFogelmanDRSchreibmanSM. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol2008;61:167175.

    • Search Google Scholar
    • Export Citation
  • 204.

    ReniMCordioSMilandriC. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol2005;6:369376.

    • Search Google Scholar
    • Export Citation
  • 205.

    ColucciGGiulianiFGebbiaV. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer2002;94:902910.

    • Search Google Scholar
    • Export Citation
  • 206.

    HerrmannRBodokyGRuhstallerT. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol2007;25:22122217.

    • Search Google Scholar
    • Export Citation
  • 207.

    LouvetCHinckeALabiancaRHeinemannV. Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 4003

    • Search Google Scholar
    • Export Citation
  • 208.

    HeinemannVQuietzschDGieselerF. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol2006;24:39463952.

    • Search Google Scholar
    • Export Citation
  • 209.

    LouvetCLabiancaRHammelR. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol2005;23:35093516.

    • Search Google Scholar
    • Export Citation
  • 210.

    Rocha LimaCMGreenMRRotcheR. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol2004;22:37763783.

    • Search Google Scholar
    • Export Citation
  • 211.

    BerlinJDCatalanoPThomasJP. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol2002;20:32703275.

    • Search Google Scholar
    • Export Citation
  • 212.

    HeinemannVBoeckSHinkeA. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer2008;8:82.

    • Search Google Scholar
    • Export Citation
  • 213.

    HeinemannVHinkeABoeckSLouvetC. Benefit from gemcitabine-based combination treatment in advanced pancreatic cancer: a meta-analysis of randomized trials [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21 2007; Orlando Florida. Abstract 129.

    • Search Google Scholar
    • Export Citation
  • 214.

    ColucciGLabiancaRDi CostanzoF. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol2010;28:16451651.

    • Search Google Scholar
    • Export Citation
  • 215.

    CunninghamDChauIStockenDD. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol2009;27:55135518.

    • Search Google Scholar
    • Export Citation
  • 216.

    StefanssonOAJonassonJGJohannssonOT. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res2009;11:R47.

    • Search Google Scholar
    • Export Citation
  • 217.

    MajdakEJDebniakJMilczekT. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer2005;104:10041012.

    • Search Google Scholar
    • Export Citation
  • 218.

    FerroneCRLevineDATangLH. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol2009;27:433438.

  • 219.

    OliverGRSugarELaheruD. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma [abstract]. Presented at the 2010 ASCO Gastrointestinal Cancers Symposium; January 22–24 2010; Orlando Florida. Abstract 180.

    • Search Google Scholar
    • Export Citation
  • 220.

    BerlinJBensonABIII. Gemcitabine remains the standard of care for pancreatic cancer. Nat Rev Clin Oncol2010;7:135137.

  • 221.

    EspinzaAMKoAHVenookAP. A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine plus capecitabine in patients with advanced pancreatic and biliary carcinomas [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 4136.

    • Search Google Scholar
    • Export Citation
  • 222.

    KulkeMHTemperoMANiedzwieckiD. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol2009;27:55065512.

    • Search Google Scholar
    • Export Citation
  • 223.

    StathopoulosGPSyrigosKAravantinosG. A multicenter phase III trial comparing irinotecan-gemcitabine with gemcitabine monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer2006;95:587592.

    • Search Google Scholar
    • Export Citation
  • 224.

    XiongHQRosenbergALoBuglioA. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol2004;22:26102616.

    • Search Google Scholar
    • Export Citation
  • 225.

    KindlerHLFribergGSinghDA. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol2005;23:80338040.

    • Search Google Scholar
    • Export Citation
  • 226.

    KindlerHLNiedzwieckiDHollisD. A double-blind placebo-controlled randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303 [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 17–21 2007; Orlando Florida. Abstract 108.

    • Search Google Scholar
    • Export Citation
  • 227.

    PhilipPABenedettiJFenoglio-PreiserM. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract LBA4509.

    • Search Google Scholar
    • Export Citation
  • 228.

    MooreMJGoldsteinDHammJ. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:19601966.

    • Search Google Scholar
    • Export Citation
  • 229.

    van CutsemEVervenneWLBennounaJ. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol2009;27:22312237.

    • Search Google Scholar
    • Export Citation
  • 230.

    ConroyTDesseigneFYchouM. Randomized phase III trial comparing FOLFIRINOX versus gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma: preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 4010.

    • Search Google Scholar
    • Export Citation
  • 231.

    Van HoffDDRamanathanRBoradM. SPARC correlation with response to gemcitabine plus nab-paclitaxel in patients with advanced metastatic pancreatic cancer: a phase I/II study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4525.

    • Search Google Scholar
    • Export Citation
  • 232.

    RothenbergMLMooreMJCrippsMC. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol1996;7:347353.

    • Search Google Scholar
    • Export Citation
  • 233.

    PelzerUKubicaKStielerJ. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4508.

    • Search Google Scholar
    • Export Citation
  • 234.

    MaiseyNChauICunninghamD. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol2002;20:31303136.

    • Search Google Scholar
    • Export Citation
  • 235.

    CartwrightTHCohnAVarkeyJA. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol2002;20:160164.

    • Search Google Scholar
    • Export Citation
  • 236.

    XiongHQVaradhacharyGRBlaisJC. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer2008;113:20462052.

    • Search Google Scholar
    • Export Citation
  • 237.

    PhilipPAMooneyMJaffeD. Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on pancreas cancer treatment. J Clin Oncol2009;27:56605669.

    • Search Google Scholar
    • Export Citation
  • 238.

    HouseMGChotiMA. Palliative therapy for pancreatic/biliary cancer. Surg Clin North Am2005;85:359371.

  • 239.

    SoderlundCLinderS. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc2006;63:986995.

    • Search Google Scholar
    • Export Citation
  • 240.

    MossACMorrisEMac MathunaP. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev2006;CD004200.

  • 241.

    MaireFHammelPPonsotP. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol2006;101:735742.

    • Search Google Scholar
    • Export Citation
  • 242.

    LillemoeKDCameronJLHardacreJM. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg1999;230:322328.

    • Search Google Scholar
    • Export Citation
  • 243.

    Van HeekNTDe CastroSMvan EijckCH. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg2003;238:894902.

    • Search Google Scholar
    • Export Citation
  • 244.

    WongGYSchroederDRCarnsPE. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA2004;291:10921099.

    • Search Google Scholar
    • Export Citation
  • 245.

    LillemoeKDCameronJLKaufmanHS. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg1993;217:447455; discussion 456–447.

    • Search Google Scholar
    • Export Citation
  • 246.

    KellerJLayerP. Human pancreatic exocrine response to nutrients in health and disease. Gut2005;54(Suppl 6):128.

  • 247.

    Dominguez-MunozJE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep2007;9:116122.

  • 248.

    KhoranaAAFrancisCWCulakovaE. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol2006;24:484490.

  • 249.

    LeeAYLevineMNBakerRI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med2003;349:146153.

    • Search Google Scholar
    • Export Citation
  • 250.

    RiessHPelzerUDeutschinoffG. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients with advanced pancreatic cancer: results of the CONKO 004 trial [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract LBA4506.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 217 217 22
PDF Downloads 22 22 3
EPUB Downloads 0 0 0